Bristol-Myers Squibb has discontinued?Daklinza?(daclatasvir) in markets where it is no longer routinely prescribed, and?there are other therapeutic options available. Daklinza?played a significant role in providing a new era of treatment, offering patients across the globe the potential for cure from?chronic HCV?infection.??New Hepatitis C treatments have built on the safety and efficacy profile of?Daklinza?to offer shorter treatment durations and a reduced pill burden, and thus providing patients more options for a potential cure.??
Following the lapse of marketing authorization in each market, the patents in that market will also be allowed to lapse. In the interim period between the lapse of a marketing authorization and patent expiry, Bristol-Myers Squibb will not enforce its patents in that market.?This policy is specific for?Daklinza?moving forward.?
For questions,?please contact the BMS Medical Information Department. Local contact information can be found at:??http://www.globalbmsmedinfo.com/